Medtech Instruments constant-currency sales growth measures revenue growth in Stryker's Instruments business after removing foreign-currency translation effects.
Stryker reported 9.0% constant-currency growth in Instruments for the second quarter of 2026. Revenue increased to $1.003B from $918M.
International growth ran faster than U.S. growth
Instruments revenue grew 8.4% in the United States and 12.3% internationally on a constant-currency basis.
The business therefore combined broad growth with a stronger international contribution.
The reorganized business scope matters
Stryker changed its organizational structure in 2026, moving Orthopaedic Instruments into Ortho Tech and combining Neuro Cranial and Enabling Technologies into Instruments, with historical periods recast.
Use it with Ortho Tech constant-currency sales growth and MedSurg and Neurotechnology operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsMedSurg and Neurotechnology product growth4 of 4 bridge concepts supportedContinue through this bridge:Endoscopy Constant-Currency GrowthMedical Constant-Currency GrowthVascular Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare surgical instruments growth
Compare Instruments growth with Stryker's 2026 organizational recast and regional mix kept explicit.
Explore more topics in the Financial Research Encyclopedia.